BIVI · Biovie Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $9.27M | $23.10M | $33.30M | $17.26M | $133.19M | $1.15M |
| SG&A | $8.57M | $8.85M | $11.55M | $9.77M | $4.64M | $1.31M |
| Total Operating Expenses | $18.07M | $32.18M | $45.08M | $27.25M | $138.05M | $2.69M |
| D&A | - | - | - | - | - | - |
| Operating Income | ($18.07M) | ($32.18M) | ($45.08M) | ($27.25M) | ($138.05M) | ($2.69M) |
| Interest Expense | $312.0K | $2.89M | $4.30M | $2.16M | $559.5K | $4.77M |
| Income Tax | - | - | - | - | - | - |
| Net Income | ($17.54M) | ($32.12M) | ($50.26M) | ($26.08M) | ($16.68M) | ($16.68M) |
| EPS - Basic | ($12.12) | ($73.00) | ($155.00) | ($106.00) | ($1482.00) | ($685.00) |
| EPS - Diluted | ($12.12) | ($73.00) | ($155.00) | ($106.00) | ($1482.00) | ($685.00) |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $17.54M | $23.84M | $19.46M | $18.64M | $4.51M | $37.2K |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $2.20M | $3.59M | $3.48M | $2.44M | $996.4K | $1.26M |
| Current Assets | $20.70M | $24.05M | $34.04M | $18.78M | $4.61M | $413.0K |
| Total Assets | $21.56M | $25.21M | $35.10M | $20.11M | $6.05M | $2.08M |
| Current Liabilities | $2.27M | $9.35M | $14.49M | $4.17M | $996.4K | $23.52M |
| Long-term Debt | - | - | - | - | - | $62.5K |
| Total Liabilities | $2.55M | $9.70M | $19.76M | $16.44M | $996.4K | $23.58M |
| Stockholders' Equity | $19.01M | $15.51M | $15.34M | $3.67M | $5.05M | ($21.50M) |
| Retained Earnings | ($352.14M) | ($334.23M) | ($301.23M) | ($250.97M) | ($224.89M) | ($41.04M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($19.03M) | ($27.95M) | ($40.25M) | ($18.99M) | ($10.45M) | ($1.63M) |
| Investing Cash Flow | - | $14.53M | ($14.30M) | - | - | - |
| Financing Cash Flow | $12.73M | $17.80M | $55.37M | $33.12M | $14.93M | $1.33M |
| CapEx | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -81.4% | -127.4% | -143.2% | -129.7% | -275.8% | -800.3% |
| Return on equity | -92.3% | -207.1% | -327.6% | -710.6% | -330.2% | 77.6% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 9.10 | 2.57 | 2.35 | 4.50 | 4.62 | 0.02 |
| Quick ratio | 9.10 | 2.57 | 2.35 | 4.50 | 4.62 | 0.02 |
| Cash ratio | 7.71 | 2.55 | 1.34 | 4.47 | 4.53 | 0.00 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | -0.00 |
| Debt / Assets | - | - | - | - | - | 0.03 |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -57.9x | -11.1x | -10.5x | -12.6x | -246.8x | -0.6x |
| Equity multiplier | 1.13 | 1.63 | 2.29 | 5.48 | 1.20 | -0.10 |
| Liabilities / Assets | 0.12 | 0.38 | 0.56 | 0.82 | 0.16 | 11.32 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 0.7x | 11.7x | 912.7x | 974.2x | 4162.8x | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 43.9% | 28.6% | -65.4% | 80.3% | -5026.6% | - |
| Net income growth (YoY) | 45.4% | 36.1% | -92.7% | -56.4% | 0.0% | - |
| EPS growth (YoY) | 83.4% | 52.9% | -46.2% | 92.8% | -116.4% | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 22.6% | 1.1% | 317.9% | -27.3% | - | - |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✓No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing BIOVIE INC. against the 5 most active filers in the same SIC group.